← Eichor
Condition: Initially Unresectable Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Initially Unresectable

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

TRANsplantation vs reSECTion After Conversion Therapy for Initially Unresectable Colorectal Liver Metastases
NA · 1 location(s) · Niguarda Hospital · NCT07607873IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non
Phase 2 · 1 location(s) · Shanghai Pulmonary Hospital, Shanghai, China · NCT07408635Ivonescimab Plus Chemotherapy in Patients With Initially Unresectable Colorectal Cancer Liver Metastases
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06848842Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebreli
Phase 2 · 1 location(s) · The Fourth Affiliated Hospital of Zhejiang University School · NCT06282445Triple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003)
Phase N/A · 4 location(s) · Fujian Provincial Hospital · NCT06561399Efficacy and Safety of Combined With Immunotherapy After Induction Therapy With Chemotherapy and Targeted Therapy in the
Phase 2 · 1 location(s) · yue junhan · NCT06176885A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cance
Phase 1/Phase 2 · 2 location(s) · Shandong Suncadia Medicine Co., Ltd. · NCT06679036Chemoradiotherapy With Surgery Followed by Consolidation Durvalumab
Phase 4 · 1 location(s) · Idris Bahce · NCT06908070Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment
Phase 2 · 1 location(s) · University of Chicago · NCT06669572Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma
NA · 1 location(s) · Peking University Cancer Hospital & Institute · NCT04047953Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases
Phase 3 · 1 location(s) · Fudan University · NCT04687631Combination of Gemcitabine, Albumin-paclitaxel , Sintilimab and Bevacizumab in Unresectable Gallbladder Cancer
Phase 2 · 1 location(s) · Lu Wang, MD, PhD · NCT05757336FOLFOX-HAIC as Conversion Treatment for Initially Unresectable Colorectal Liver Metastasis
Phase 2 · 1 location(s) · Tongji Hospital · NCT06988852FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevaciz
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT05727163Induction Treatment for Initially Unresectable Colorectal Liver Metastases: Combined Hepatic Arterial Infusion Pump Ther
Phase 3 · 1 location(s) · The Netherlands Cancer Institute · NCT06857773Oncolytic Virus in Esophageal Squamous Cell Carcinoma
Phase 1/Phase 2 · 1 location(s) · Sichuan University · NCT07061704An Initial Evaluation of AN8025 in Solid Tumors
Phase 1 · 1 location(s) · Adlai Nortye Biopharma Co., Ltd. · NCT07639047A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Bili
Phase 3 · 174 location(s) · AstraZeneca · NCT07221253SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC
Phase 2/Phase 3 · 1 location(s) · Second Affiliated Hospital of Nanchang University · NCT07131319A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initial
Phase 2 · 1 location(s) · Yongjun Chen · NCT07135544
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.